ISHL12 2022 | An insight into the HoLISTIC consortium and the value of international collaborations in HL
Andrew Evens, DO, MBA, FACP, Rutgers University, New Brunswick, NJ, shares some insights into emerging international collaborations in Hodgkin lymphoma (HL), drawing focus on the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) consortium, which stores and analyzes over 10,000 records concerning HL. Dr Evens discusses the various Phase II and Phase III trials and resources that are offered to both providers and patients, as well as the future goals of the HoLISTIC consortium. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Grant/Research Support: ORIEN and Leukemia & Lymphoma Society,
Advisory Board (Research Related): Seattle Genetics, Hutchmed, Incyte, Daiichi Sankyo, and Epizyme
Consultant (Educational Related): Research to Practice, Curio, Cota, Patient Power, Curio Science, and OncLive
Consultant (Data and Safety Monitoring Board): Novartis, Abbvie, and Pharmacyclics
